首页 | 本学科首页   官方微博 | 高级检索  
检索        

柴胡疏肝散联合加巴喷丁治疗PHN患者的疗效及对炎症指标、疼痛相关物质及神经相关因子的影响
引用本文:王楠楠,付金霞,张贺男,车飞,王建东.柴胡疏肝散联合加巴喷丁治疗PHN患者的疗效及对炎症指标、疼痛相关物质及神经相关因子的影响[J].中国医院药学杂志,2019,39(24):2542-2546.
作者姓名:王楠楠  付金霞  张贺男  车飞  王建东
作者单位:1. 齐齐哈尔医学院附属二医院神经内二科, 黑龙江 齐齐哈尔 161000;2. 齐齐哈尔医学院附属二医院神经内三科, 黑龙江 齐齐哈尔 161000
基金项目:2016年齐齐哈尔市科技局社会发展计划指令项目(编号:SFGG-2016)
摘    要:目的:探讨柴胡疏肝散联合加巴喷丁对带状疱疹后遗神经痛(PHN)患者疼痛疗效、炎症指标、疼痛相关物质及神经相关因子的影响。方法:选择在院治疗的100例PHN患者作为研究对象,将其分为对照组及观察组,各50例。对照组采用加巴喷丁胶囊口服,观察组在对照组基础上加用柴胡舒肝散。观察比较各组疼痛疗效、炎症指标、疼痛相关物质及神经相关因子的表达水平,并同时记录2组患者的不良反应。结果:治疗前,观察组与对照组的炎症指标、疼痛相关物质及神经相关因子水平差异不显著(P>0.05),治疗后,观察组较对照组疼痛状况减轻明显(P<0.05)。同组治疗1,2周后分别与治疗前相比,白介素-2(IL-2)、β-内啡肽(β-EP)及脑源性神经营养因子(BDNF)水平显著升高(P<0.05),白介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、神经肽Y (NPY)、P物质(SP)、S100β蛋白及神经元特异性烯醇化酶(NSE)水平显著下降(P<0.05),且同组治疗2周后与治疗1周后相比,IL-2、β-EP及BDNF水平升高明显(P<0.05),IL-6、TNF-α、NPY、SP、S100β及NSE水平下降明显(P<0.05)。与对照组治疗1,2周后分别比较,观察组治疗1,2周后IL-2、β-EP及BDNF水平显著升高(P<0.05),IL-6、TNF-α、NPY、SP、S100β及NSE水平显著下降(P<0.05)。且2组患者的不良反应总发生率无显著性差异(P>0.05)。结论:柴胡疏肝散联合加巴喷丁治疗PHN患者能显著缓解疼痛状况,减轻炎症并保护神经。

关 键 词:带状疱疹后遗神经痛  疼痛  炎症  神经  
收稿时间:2019-04-23

Effects of Chaihu Shugan powder combined with gabapentin on pain efficacy,inflammatory index,pain-related substances and neuro-related factors in patients with PHN
WANG Nan-nan,FU Jin-xia,ZHANG He-nan,CHE Fei,WANG Jian-dong.Effects of Chaihu Shugan powder combined with gabapentin on pain efficacy,inflammatory index,pain-related substances and neuro-related factors in patients with PHN[J].Chinese Journal of Hospital Pharmacy,2019,39(24):2542-2546.
Authors:WANG Nan-nan  FU Jin-xia  ZHANG He-nan  CHE Fei  WANG Jian-dong
Institution:1. Second department of Neurology, Second affiliated Hospital of Qiqihar Medical College, Heilongjiang Qiqihar 161000, China;2. Third department of Neurology, Second affiliated Hospital of Qiqihar Medical College, Heilongjiang Qiqihar 161000, China
Abstract:OBJECTIVE To investigate the effects of Chaihu Shugan powder combined with gabapentin on pain, inflammatory indexes, pain-related substances and neuro-related factors in patients with postherpetic neuralgia (PHN).METHODS 100 patients with PHN treated in our hospital from June 2016 to March 2018 were divided into control group and observation group, 50 cases in each group. The control group was treated with gabapentin capsule, and the observation group was added with Chaihu Shugan powder on the basis of the control group. The levels of pain, inflammation, pain related substances and nerve related factors in each group were observed and compared. And the adverse reactions of the two groups were recorded at the same time.RESULTS Before treatment, there was no significant difference in inflammatory markers, pain-related substances and neuro-related factors between the observation group and the control group (P>0.05), After treatment, the pain status of the observation group was significantly lower than that of the control group (P<0.05). The same group was treated for 1 and 2 weeks, respectively, compared with that before treatment, the levels of IL-2, β-EP and BDNF were significantly higher (P<0.05), while the levels of IL-6, TNF-α, NPY, SP, S100β protein and NSE were significantly lower (P<0.05). The levels of IL-2, β-EP and BDNF increased significantly (P<0.05) and the levels of IL-6, TNF-α, NPY, SP, S100β and NSE were decreased significantly (P<0.05) in the same group after 2-week and 1-week of treatment (P<0.05). After 1 and 2-week of treatment, the levels of IL-2, β-EP and BDNF in the observation group were significantly higher than those in the control group (P<0.05), while the levels of IL-6, TNF-α, NPY, SP, S100β and NSE were significantly lower (P<0.05). Besides, there was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05).CONCLUSION Chaihu Shugan powder combined with gabapentin can significantly relieve pain condition, reduce inflammation and protect nerves in patients with PHN.
Keywords:postherpetic neuralgia  pain  inflammation  nerve  
点击此处可从《中国医院药学杂志》浏览原始摘要信息
点击此处可从《中国医院药学杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号